Psychedelics and psychedelic assisted therapies have become the new darling of the health industry. Ketamine is now popularly prescribed as an off-label mental-health treatment. Colorado and Oregon have both legalized psilocybin and other “natural medicines” under state law for therapeutic and medicinal use. And Lykos Therapeutics has sought FDA approval for a new drug application for MDMA. All of these efforts are premised on providing new approaches to addressing mental health and wellness. But what are the legal constraints for use of psychedelics in a therapeutic and medical setting? And what should clinicians do to protect themselves if they want to incorporate these substances into an overall treatment plan? Deborah’s talk will provide an overview of the laws governing psychedelic therapies and provide strategies for avoiding legal minefields.
Learning Objectives:
Identify the conditions for which ibogaine therapy can be considered a treatment.
Review where this therapy is available legally.
Identify how psychedelic therapy with a specific substance unfolds and is administered.
Review what the legal landscape for drug reform looks like in the US in practice.
